logo
Stock market today: Wall Street drifts lower, dragged down by tech and anxiety over China tariffs

Stock market today: Wall Street drifts lower, dragged down by tech and anxiety over China tariffs

The Hill05-02-2025

Wall Street shifted lower in early trading Wednesday as markets took in more corporate earnings reports while considering the impact of tariffs being imposed by the United States and China.
Futures for the S&P 500 were off 0.4%, while technology stocks dragged Nasdaq futures down 0.8% before the bell. Futures for the Dow Jones Industrials were off 0.1%.
Google parent company Alphabet tumbled 7.1% after its latest earnings report disappointed investors, who had been expecting more robust revenue from the company's cloud business related to artificial intelligence.
Despite beating analysts' sales and profit targets for the most recent quarter, shares of Advanced Micro Devices skidded nearly 10% as revenue from its data centers fell short of Wall Street expectations.
Walt Disney Co. shares rose about 1% after the entertainment giant beat first-quarter profit expectations thanks in part to the box office success of 'Moana 2.'
Mattel soared more than 13% in premarket after the toy and game maker beat Wall Street's earnings projections and gave a strong profit outlook for 2025.
Some analysts see tariffs on China as separate from Trump's moves against other trading partners. Trump may be more likely to keep tariffs on China longer, as he did in his first presidential term, to separate the United States more from its geopolitical rival.
Trump is pressing ahead with a 10% tariff on U.S. companies importing things from China. And China retaliated on Tuesday by announcing its own tariffs on some U.S. products and an antitrust investigation into Google.
Media reports on Wednesday suggested that Chinese regulators are considering a similar probe in to Apple's App Store policies. Shares of Apple slid more than 2% before the bell.
China's 15% tariff on U.S. coal and liquefied natural gas products, as well as a 10% tariff on crude oil, agricultural machinery and large-engine cars imported from the United States won't take effect until Monday. That leaves time for negotiations between Trump and Chinese President Xi Jinping.
'Trade tensions haven't exploded yet, but they're simmering dangerously close to a full boil, and anyone brushing them off does so at their own risk,' said Stephen Innes, managing partner at SPI Asset Management.
Trump on Monday agreed to delay his taxes on U.S. imports of Canadian and Mexican products for a month. Some traders hope Trump would likely be turned off by the damage Wall Street would take if a worst-case, long-term trade war were to occur. Trump has pointed in the past to the stock market as a real-time measure of his performance.
But a trade war is still possible, and some analysts say more swings may be coming because Trump's threats should be taken seriously.
At midday in Europe, France's CAC 40 shed 0.2%, while Germany's DAX fell 0.1%. Britain's FTSE 100 was up 0.2%.
Earlier in the global day in Asia, Japan's benchmark Nikkei 225 recouped earlier losses and was little changed, finishing up less than 0.1% at 38,831.48.
Among Japanese issues, the stock price of Honda Motor Co. shot up 8.2% after Japanese media reports said its talks to set up a joint holding company with rival Nissan Motor Corp. were unraveling. Nissan stock tumbled 4.9%.
Australia's S&P/ASX 200 rose 0.5% to 8,416.90. The Hang Seng dropped 0.9% to 20,597.09, while the Shanghai Composite lost 0.7% to 3,229.49.
South Korea's Kospi jumped 1.1% to 2,509.27, as investors found bargains after the recent price dips and found optimism from the overnight Wall Street rally.
In energy trading, benchmark U.S. crude fell 83 cents to $71.89 a barrel. Brent crude, the international standard, declined 88 cents to $75.32 a barrel.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Wedbush Reiterates $270 Target on Apple (AAPL), Citing Hopes for AI Execution
Wedbush Reiterates $270 Target on Apple (AAPL), Citing Hopes for AI Execution

Yahoo

time24 minutes ago

  • Yahoo

Wedbush Reiterates $270 Target on Apple (AAPL), Citing Hopes for AI Execution

Apple Inc. (NASDAQ:AAPL) is one of the 10 best tech stocks to buy according to billionaires right now. On June 10, following Apple's keynote at the 2025 Worldwide Developers Conference (WWDC), Wedbush analyst Daniel Ives reaffirmed his Outperform rating on the stock, along with a $270 price target. In his post-event note, Ives noted that while the presentation outlined Apple's vision for the developer ecosystem, it offered limited new detail on the company's artificial intelligence initiatives, an area where Apple appears to be moving cautiously, likely in response to last year's strategic missteps. A wide view of an Apple store, showing the range of products the company offers. Notably, at the WWDC 2024, the company had given an ambitious roadmap to its Apple Intelligence and a transformation for smart AI assistant, Siri. However, the execution over these plans has lagged and the company's AI strategy has been under scrutiny. Fast forwarding to now, Ives believes Apple's measured approach is understandable, but 2025 could be a critical year for the company to begin monetizing its AI efforts more visibly. He suggested that if internal development does not accelerate, the company may need to explore larger-scale AI acquisitions to strengthen its positioning in the space. Although Apple may be seen as entering the AI race later than peers, Ives acknowledged that the company has begun laying the groundwork for a longer-term strategy. In his view, WWDC marked the start of Apple's multi-year AI roadmap, with initial steps that could shape its direction through 2026 and beyond. Apple Inc. (NASDAQ:AAPL) designs, manufactures, and markets innovative products, including the iPhone, iPad, Mac computers, Apple Watch, and Apple TV. The company also offers a range of software and services, such as the iOS and macOS operating systems, iCloud, advertising, payment services, Apple Music, and the App Store. While we acknowledge the potential of AAPL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

Cantor Fitzgerald Initiates Coverage on Docebo (DCBO) With an Overweight Rating
Cantor Fitzgerald Initiates Coverage on Docebo (DCBO) With an Overweight Rating

Yahoo

time30 minutes ago

  • Yahoo

Cantor Fitzgerald Initiates Coverage on Docebo (DCBO) With an Overweight Rating

Docebo Inc. (NASDAQ:DCBO) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 9, analyst Yi Fu Lee from Cantor Fitzgerald initiated coverage on Docebo Inc. (NASDAQ:DCBO) assigning an Overweight rating with a price target of $35 on the stock. This marks the first rating on the stock from Cantor Fitzgerald indicating firms' confidence in the company's potential and the overall industry condition. Docebo Inc. (NASDAQ:DCBO) is a leading learning platform that uses AI and innovation as its backbone. The company announced results for its fiscal first quarter of 2025 on March 9. The subscription revenue grew 13% year-over-year to $54.2 million, representing 95% of the total revenue. Whereas the total revenue also grew 11% year-over-year to $57.3 million. Notably, net income came in at $1.5 million. Both the revenue and EPS exceed market expectations, with revenue beating the consensus by $0.2 million and EPS topped by $0.05. A professional instructor delivering a customer education workshop. Management is anticipating second-quarter revenue between $59.0 million and $59.2 million. It expects subscription revenue to grow about 1.5% higher than overall company revenue. Docebo Inc. (NASDAQ:DCBO) provides an AI-powered learning platform that helps organizations create, manage, and deliver personalized training programs at scale. The company's platform enables organizations to deliver advanced learning experiences for its employees to drive measurable growth. While we acknowledge the potential of DCBO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

Raymond James Resumes Coverage on Disc Medicine (IRON) With a Strong Buy Rating
Raymond James Resumes Coverage on Disc Medicine (IRON) With a Strong Buy Rating

Yahoo

time30 minutes ago

  • Yahoo

Raymond James Resumes Coverage on Disc Medicine (IRON) With a Strong Buy Rating

Disc Medicine, Inc. (NASDAQ:IRON) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 11, analysts from Raymond James resumed coverage of Disc Medicine, Inc. (NASDAQ:IRON) with a strong Buy rating and a price target of $89. The resumed coverage comes as the company released its research note on Biotech names. The firm highlighted a favorable risk/reward profile in the biotech sector. It noted that while companies with a high probability of success for lead assets inspire higher conviction, investments in less de-risked assets like Disc Medicine, Inc. (NASDAQ:IRON) could yield the most outsized returns. The firm sees more than $1 billion potential for the company's drug bitopertin, with an expected market penetration of about 30%-35%, owing to its disease-modifying agent capabilities X-linked protoporphyria. A scientist in a laboratory setting examining a sample of blood with a microscope. Disc Medicine, Inc. (NASDAQ:IRON) is a clinical-stage biopharmaceutical company focused on discovering therapies for serious hematologic diseases. Its pipeline includes drug candidates like bitopertin for erythropoietic porphyrias and Diamond-Blackfan Anemia, DISC-0974 for anemia related to myelofibrosis and chronic kidney disease, and DISC-3405 for polycythemia vera and other blood disorders. While we acknowledge the potential of IRON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store